High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors
Yunan Nie, Alyse Staley, Trista K. Hinz, Rocio Perez-Johnston, Daniel T. Merrick, Michael C. Yang, Kurtis D. Davies, Paul A. Bunn, Dara L. Aisner, D Ross Camidge, Erin L. Schenk, Lynn E. Heasley, Tejas Patil · 2026
Read High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase Inhibitors by Yunan Nie, Alyse Staley, Trista K. Hinz, Rocio Perez-Johnston, Daniel T. Merrick, Michael C. Yang, Kurtis D. Davies, Paul A. Bunn, Dara L. Aisner, D Ross Camidge, Erin L. Schenk, Lynn E. Heasley, Tejas Patil (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13492699.txt.
Description
Yunan Nie and co-authors ask whether a common immune marker predicts how long targeted drugs hold back a gene-driven lung cancer. The cancer carries a rearranged ALK gene and is treated first with ALK-blocking pills, which rarely benefit from immunotherapy even though the marker PD-L1 is often high. The team reviewed 130 patients treated at one university center.
Forty-four percent had high PD-L1 levels. After adjusting for other factors, those patients went a median of eleven months before their cancer progressed, against twenty-one months for low-marker patients. Overall survival and response rates did not differ by marker level. Lab work with mouse cancer cells engineered to overproduce the marker explored why the pills might falter sooner. The marker may help doctors counsel patients on likely drug durability.
Catalog record
| CREATOR | Yunan Nie, Alyse Staley, Trista K. Hinz, Rocio Perez-Johnston, Daniel T. Merrick, Michael C. Yang, Kurtis D. Davies, Paul A. Bunn, Dara L. Aisner, D Ross Camidge, Erin L. Schenk, Lynn E. Heasley, Tejas Patil |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |